

US005772998A

# United States Patent [19]

Dasch et al.

[11] Patent Number:

5,772,998

[45] Date of Patent:

Jun. 30, 1998

[54] MONOCLONAL ANTIBODIES TO TRANSFORMING GROWTH FACTOR-BETA AND METHODS OF USE

[75] Inventors: James R. Dasch, Palo Alto; Doran R. Pace, III, San Francisco; Wendy O. Waegell, Mountain View, all of Calif.

[73] Assignee: Celtrix Pharmaceuticals, Inc., Santa Clara, Calif.

[21.] Appl. No.: 434,976

[22] Filed: May 4, 1995

# Related U.S. Application Data

- [62] Division of Ser. No. 759,109, Sep. 6, 1991, Pat. No. 5,571, 714, which is a continuation of Ser. No. 288,432, Dec. 22, 1988, abandoned.
- [51] Int. Cl.<sup>6</sup> ...... A61K 39/395; C07K 16/22
- [58] Field of Search \_\_\_\_\_\_\_ 424/145.1, 158.1, 424/198.1, 133.1; 435/70.21, 172.2, 240.27; 530/388.23, 388.24, 389.2, 399, 387.3

## [56] References Cited

# U.S. PATENT DOCUMENTS

4,774,322 9/1988 Seyedin et al. .

#### FOREIGN PATENT DOCUMENTS

0455482 11/1991 European Pat Off. . WO 91/19513 12/1991 WIPO . WO 94/18991 9/1994 WIPO .

# OTHER PUBLICATIONS

Roberts et al., "Type β transforming growth factor: a bifunctional regulator of cellular growth" *Proc. Natl. Acad. Sci. USA* (1985) 82:119–123.

Hayashi et al., "Differential effects of TGF-β<sub>1</sub> on lymphohemopolesis in long-term bone marrow cultures" *Blood* (1989) 74(5):1711-1717.

Carlino et al., "Transforming growth factor β1 systematically modulates granuloid, erythroid, lymphoid, and thrombocytic cells in mice" *Exp. Hematol.* (1992) 20:943–950.

Han et al., "Megakaryocytopoiesis: characterization and regulation in normal and pathologic states" Int. J. Hematol. (1991) 54(1):3-14.

Ishibashi et al., "Type β transforming growth factor is a potent inhibitor of murine megakaryocytopoiesis in vitro" *Blood* (1987) 69:1737–1741.

Keller et al., "Transforming growth factor β directly regulates primitive murine hematopoietic cell proliferation" Blood (1990) 75:596–602.

Cashman et al., "Mechanisms that regulate the cell cycle of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β" Blood (1990) 75(1):96-101.

Ellingsworth et al., "Antibodies to the N-terminal portion of cartilage-inducing factor A and transforming growth factor  $\beta$ " J. Biol. Chem. (1986) 261:12362-12367.

Eaves et al., "Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer" Blood (1991) 78(1):110-117.

Hatzfeld et al., "Release of early human hematopoietic progenitors form quiescence by antisense transforming growth factor β1 or Rb oligonucleotides" J. Exp. Med. (1991) 174:925–929.

Wang et al., "Expression cloning and characterization of the TGF-\$\beta\$ type III receptor" Cell (1991) 67:797-805.

Jordan et al., "Cellular and developmental properties of fetal hematopoetic stem cells" Cell (1990) 61;953–963.

Waegell et al., "Neutralizing antibody to TGF-β overcomes normal growth controls in long-term bone marrow cultures" J. Cell. Biochem. (1992) 16:92 (abstract No. M342).

Dasch et al., "Monoclonal antibodies recognizing transforming growth factor  $\beta$ . Bioactivity neutralization and transforming growth factor  $\beta$ 2 affinity purification" J. Immunol. (1989) 142:1536–1547.

Herlyn et al., "Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro" Adv. Cancer. Res. (1990) 54:213-234.

Harris et al., "Therapeutic antibodies—the coming of age" TIBTECH (1993) 11:42-44.

Lucas et al., "The autocrine production of transforming growth factor— $\beta_1$  during lymphocyte activation" J. Inumunol. (1990) 145:1415—1422.

Gaifre et al., "Preparation of monoclonal antibodies: strategies and procedures" Meth. Enzymol. (1981) 73:3-46.

Cheifetz et al., "The transforming growth factor-β system: A complex pattern of cross-reactive ligands and receptors" Cell (1987) 48:409-416.

Ellingsworth et al., "Transforming growth factor-\( \beta \)s are equipotent growth inhibitors of interleukin-1-induced thymocyte proliferation" Cell. Immunol. (1988) 114:41-54. "Kehrl et al., "Production of transforming growth factor-\( \beta \)by human T lymphocytes and its potential role in the regulation of T cell growth" J. Exp. Med. (1986) 163:1037-1050.

Kehrl et al., "Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes" J. Immunol. (1986) 137:3855–3860.

Keller et al., "Transforming growth factor  $\beta$ -1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines" J. Exp. Med. (1988) 168:737-750.

Keski-Oja et al., "Immunodetection and modulation of cellular growth with antibodies against mative transforming growth factor- $\beta^1$ " Cancer Res. (1987) 47:6451-6458.

(List continued on next page.)

Primary Examiner—Robert D. Budens Attorney, Agent, or Firm—Morrison & Foerster, LLP

# [57] ABSTRACT

Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.

#### 7 Claims, 5 Drawing Sheets